To the Editor: We read with great interest Case 26–1978 in the July 6 issue of the Journal, which discussed a patient with drug-induced toxic epidermal necrolysis, and should like to report on a similar case in which this serious complication was considered to be secondary to mithramycin, an anti-tumor antibiotic used against embryonal carcinoma of testicular origin, brain tumors and often as therapy for hypercalcemia due to cancer.A 22-year-old man with Stage III embryonal testicular carcinoma had received combination chemotherapy over a 12-month period that resulted in a temporary partial remission. Brain metastases and progression of the . . .